Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Rating) saw a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 734,300 shares, a growth of 5.5% from the August 15th total of 695,900 shares. Based on an average trading volume of 221,200 shares, the days-to-cover ratio is currently 3.3 days. Approximately 3.5% of the company’s shares are sold short.
Insiders Place Their Bets
In other news, major shareholder Holdings A/S Novo sold 800,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 13th. The stock was sold at an average price of $2.00, for a total value of $1,600,000.00. Following the completion of the sale, the insider now directly owns 3,703,991 shares of the company’s stock, valued at approximately $7,407,982. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 22.90% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the business. Cubist Systematic Strategies LLC bought a new stake in shares of Bolt Biotherapeutics during the 2nd quarter worth approximately $30,000. Prudential Financial Inc. bought a new stake in shares of Bolt Biotherapeutics during the second quarter worth $33,000. PDT Partners LLC bought a new stake in shares of Bolt Biotherapeutics during the first quarter worth $33,000. Occudo Quantitative Strategies LP boosted its stake in shares of Bolt Biotherapeutics by 19.5% during the second quarter. Occudo Quantitative Strategies LP now owns 30,816 shares of the company’s stock valued at $63,000 after purchasing an additional 5,028 shares during the period. Finally, Marquette Asset Management LLC bought a new position in shares of Bolt Biotherapeutics in the second quarter worth about $130,000. Institutional investors own 69.25% of the company’s stock.
Wall Street Analyst Weigh In
Bolt Biotherapeutics Stock Performance
Bolt Biotherapeutics stock opened at $1.76 on Wednesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 9.73 and a quick ratio of 9.73. The firm has a market capitalization of $66.25 million, a P/E ratio of -0.67 and a beta of 1.01. Bolt Biotherapeutics has a 1-year low of $1.39 and a 1-year high of $14.98. The company’s 50-day moving average is $2.11 and its 200 day moving average is $2.16.
Bolt Biotherapeutics Company Profile
Bolt Biotherapeutics, Inc, a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages.
- Get a free copy of the StockNews.com research report on Bolt Biotherapeutics (BOLT)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Has AMD stock stock fallen too far?
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.